INS and diabetes mellitus: Recent guidelines by the American Diabetes Association and the European Association for the Study of Diabetes recommend that for most such patients, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are preferable to insulin as the initial injection therapy and are also the preferred choice for addition to basal insulin for combination injection therapy [3].